Conventional chemotherapeutic agents do not preferentially localize at the site of disease, which may cause unnecessary toxicity and prevent escalation to therapeutic active regimens.
Philochem uses state-of-the-art technologies to discover and develop novel therapeutics based on small organic ligands, cyclic peptides, and antibody fragments.
The approach crucially relies on the identification of accessible markers of disease and on the discovery of high affinity ligands, which facilitate pharmacodelivery applications.
Philochem develops product candidates, validates them in relevant models of disease and moves the most promising agents to clinical trials. While most activity are focused on oncology, the potential of Philochem’s approach extends to other disease areas, including chronic inflammation.
Zana et al,. (2022), Clin Cancer Res CCR-22-1788
Galbiati et al. (2022) J Nucl Med, numed.122.264036
Backhaus et al. (2021) Eur J Nucl Med Mol Imaging, 10.21203/rs.3.rs-969176/v1
Millul et al. (2021) PNAS, 118, 16, e2101852118
Cazzamalli et al. (2018) Clin Cancer Res, 24, 3656-67
Wichert et al. (2015) Nat Chem, 7, 241-9
A Small-Molecule Drug Conjugate for the Treatment of Carbonic Anhydrase IX Expressing Tumors
Krall et al. (2014) Angew Chem Int Ed, 53, 4231-5
Neri and Supuran (2011) Nat Rev Drug Discov, 10, 767-77
Neri and Bicknell (2005) Nat Rev Cancer, 5, 436-46